Merakris Therapeutics Inc.
Hillsborough, NC
- UEI
- E55DU16Y1VN7
- CAGE
- 13HN2
- Primary NAICS
- 339113 Surgical Appliance and Supplies Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing
- 339112 Surgical and Medical Instrument Manufacturing
- 541611 Administrative Management and General Management Consulting Services
- 541618 Other Management Consulting Services
- 541690 Other Scientific and Technical Consulting Services
- 541713 Research and Development in Nanotechnology
- SAM.gov registration date
- Physical address
- 612 Victoria Dr N, Hillsborough, NC 27278, USA
- Website
- merakris.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $16,838 |
| FY2025 | $16,838 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $16,838 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Dermacyte | Veterans Integrated Service Network 22 (VHA) | $16,838 | |
| Prosthetics:implant | Veterans Integrated Service Network 22 (VHA) | $16,838 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Evaluation of efficacy and safety of MTX-001 in diabetic foot ulcers | National Institute of Diabetes and Digestive and Kidney Diseases (NIH) | $2,219,008 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Endologix LLC | Santa Rosa, CA | 339113 Surgical Appliance and Supplies Manufacturing |
| Medshape, Inc. | Atlanta, GA | 339112 Surgical and Medical Instrument Manufacturing |
| Synapse Biomedical, Inc. | Oberlin, OH | 339112 Surgical and Medical Instrument Manufacturing |
| Sandhills Orthotics LLC | Pinehurst, NC | 621399 Offices of All Other Miscellaneous Health Practitioners |
| Otto Bock Healthcare LP | Austin, TX | 339113 Surgical Appliance and Supplies Manufacturing |
About the company
Merakris Therapeutics Inc., a for-profit medical device manufacturer based in Hillsborough, North Carolina, supplies prosthetic implants, biologic wound-healing therapies, and medical equipment to the Department of Veterans Affairs and the National Institutes of Health as a prime contractor and federal grant recipient, competing without set-aside designation.
The vendor's recent federal footprint spans three customer agencies, all concentrated in healthcare and biomedical research. The Department of Veterans Affairs Veterans Health Administration dominates by dollar value: Veterans Integrated Service Network 12 anchors $46.4 million through a GSA Federal Supply Schedule 65 II A Medical Equipment & Supplies contract awarded June 15, 2026, with a five-year ceiling running through June 14, 2031. Veterans Integrated Service Network 22 has issued two smaller purchase orders totaling $33.7 thousand for Dermacyte (awarded April 21, 2026, completing June 30, 2026) and prosthetic implants (awarded August 1, 2025, completing September 30, 2025). The National Institute of Diabetes and Digestive and Kidney Diseases awarded Merakris a $2.2 million direct-to-Phase II Small Business Innovation Research grant (CFDA 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research) on July 20, 2026, to conduct a Phase II clinical trial evaluating MTX-001, a first-in-class biologic with anti-inflammatory, antimicrobial, anti-proteolytic, and pro-growth functions, for treating diabetic foot ulcers. Preliminary Phase II data from venous leg ulcer treatment showed 83 percent average wound-size reduction and significant pain reduction over 12 weeks. The grant runs through May 31, 2028.
The vendor operates exclusively as a prime across four total awards with combined potential value of $46.5 million, of which $2.3 million has been obligated as of the source date. One award (the VISN 22 purchase order for Dermacyte) reaches completion within the next twenty-four months. Activity is nascent — one award in 2025, three in 2026 — with no subcontractor footprint in the source data.
Quick answers
Is Merakris Therapeutics Inc. registered in SAM.gov?
Yes. Merakris Therapeutics Inc.'s SAM.gov registration is active through June 19, 2027.
What is Merakris Therapeutics Inc.'s CAGE code?
Merakris Therapeutics Inc.'s CAGE code is 13HN2, and its Unique Entity ID (UEI) is E55DU16Y1VN7.
Which contract vehicles does Merakris Therapeutics Inc. hold?
Merakris Therapeutics Inc. holds a place on 1 federal contract vehicle: FSS-65-II-A.
How much has Merakris Therapeutics Inc. received in federal contracts?
Federal contracts obligated $16,838 to Merakris Therapeutics Inc. in fiscal year 2025 and $33,676 in fiscal years 2023 through 2027.
What is Merakris Therapeutics Inc.'s most recent federal award?
Merakris Therapeutics Inc.'s most recent federal grant award is Evaluation of efficacy and safety of MTX-001 in diabetic foot ulcers (R44DK146625), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on July 20, 2026.
On GovTribe
See Merakris Therapeutics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors